A real-world study of carrellizumab in the treatment of patients with malignant solid tumors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048691

Enrollment

Unknown

Registered

2021-07-12

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumors

Interventions

Case series:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years; 2.Patients with malignant solid tumors diagnosed by histopathological or cytological examinations (Patients with primary liver cancer can meet the clinical diagnostic criteria of the "Diagnosis and Treatment Specifications for Primary Liver Cancer" (2019 Edition)); 3 According to the RECIST 1.1 standard, there is at least one measurable target lesion; 4.The physician believes that it may benefit from carrellizumab treatment and voluntarily accepts the treatment; 5.Sign informed consent.

Exclusion criteria

Exclusion criteria: 1.Women during pregnancy or lactation; 2.Patients who have hypersensitivity to the active ingredient of carrellizumab or any of the excipients listed in [ingredients]; 3.Participate in any research with intervention measures outside of routine clinical practice; 4.The investigator judges other conditions that may affect the conduct of clinical research and the determination of research results.

Design outcomes

Primary

Measure	Time frame
progression free survival;objective remission rate;Disease Control Rate;overall survival;safety;	—

Countries

China

Contacts

Public ContactXu Yinghua

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

xyh7003@zju.edu.cn+86 13666627003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026